Brokerages Set Johnson & Johnson (NYSE:JNJ) Price Target at $175.93

Johnson & Johnson (NYSE:JNJ) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $175.93.

Several research analysts have recently issued reports on the company. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Wells Fargo & Company lifted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Royal Bank of Canada lifted their price target on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Sanford C. Bernstein lifted their price target on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Finally, TD Cowen reduced their price target on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th.

Johnson & Johnson Trading Down 0.5 %

Johnson & Johnson stock opened at $159.86 on Tuesday. The stock has a 50-day moving average of $163.39 and a two-hundred day moving average of $155.35. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85. The stock has a market cap of $384.88 billion, a PE ratio of 23.13, a price-to-earnings-growth ratio of 2.90 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period last year, the business posted $2.66 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

A number of institutional investors have recently made changes to their positions in JNJ. LS Investment Advisors LLC boosted its stake in Johnson & Johnson by 2.3% during the third quarter. LS Investment Advisors LLC now owns 15,742 shares of the company’s stock worth $2,551,000 after buying an additional 353 shares during the last quarter. Trinity Legacy Partners LLC boosted its stake in Johnson & Johnson by 11.9% during the third quarter. Trinity Legacy Partners LLC now owns 35,375 shares of the company’s stock worth $5,717,000 after buying an additional 3,759 shares during the last quarter. Beacon Harbor Wealth Advisors Inc. boosted its stake in Johnson & Johnson by 0.4% during the third quarter. Beacon Harbor Wealth Advisors Inc. now owns 47,498 shares of the company’s stock worth $7,698,000 after buying an additional 175 shares during the last quarter. Portside Wealth Group LLC boosted its stake in Johnson & Johnson by 7.0% during the third quarter. Portside Wealth Group LLC now owns 13,429 shares of the company’s stock worth $2,176,000 after buying an additional 879 shares during the last quarter. Finally, Keynote Financial Services LLC boosted its stake in Johnson & Johnson by 3.7% during the third quarter. Keynote Financial Services LLC now owns 11,332 shares of the company’s stock worth $1,836,000 after buying an additional 408 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.